Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays

Valentini, Davide; Rao, Martin; Ferrara, Giovanni; Perkins, Marc C.; Dodoo, Ernest; Zumla, Alimuddin; Maeurer, Markus

doi:10.1016/j.ijid.2017.01.015

Cited by 6 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further analysis indicated that 150 studies involved in the peptide or epitope for TB, including 76 studies in epitope screening and prediction, 45 studies in evaluating immunogenicity, 8 studies in peptide-based vaccine construction, and 21 studies in assessing vaccine efficacy in animal models (Figure 3B and Table S1). Among these 150 articles, we found that 14 teams had published at least 3 articles in these four areas of TB epitopes or peptides, including six studies on epitope screening and prediction (181)(182)(183)(184)(185)(186) and three studies on immunogenicity (187-189) from Pro. Markus J Maeurer's team; seven studies on epitope screening and prediction from Pro.…”

Section: Research Status Of Tb Peptide-based Vaccinesmentioning

confidence: 99%

Peptide-Based Vaccines for Tuberculosis

Gong

Pan²,

Cheng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. As a result of the coronavirus disease 2019 (COVID-19) pandemic, the global TB mortality rate in 2020 is rising, making TB prevention and control more challenging. Vaccination has been considered the best approach to reduce the TB burden. Unfortunately, BCG, the only TB vaccine currently approved for use, offers some protection against childhood TB but is less effective in adults. Therefore, it is urgent to develop new TB vaccines that are more effective than BCG. Accumulating data indicated that peptides or epitopes play essential roles in bridging innate and adaptive immunity and triggering adaptive immunity. Furthermore, innovations in bioinformatics, immunoinformatics, synthetic technologies, new materials, and transgenic animal models have put wings on the research of peptide-based vaccines for TB. Hence, this review seeks to give an overview of current tools that can be used to design a peptide-based vaccine, the research status of peptide-based vaccines for TB, protein-based bacterial vaccine delivery systems, and animal models for the peptide-based vaccines. These explorations will provide approaches and strategies for developing safer and more effective peptide-based vaccines and contribute to achieving the WHO’s End TB Strategy.

show abstract

Section: Research Status Of Tb Peptide-based Vaccinesmentioning

confidence: 99%

Peptide-Based Vaccines for Tuberculosis

Gong

Pan²,

Cheng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Using the modeled structures of each variant allowed the investigation of differential B-cell epitope predictions and demonstrated high variability in the number of predicted B-cell epitopes among PPE18 variants. This observation builds on work investigating heterogeneity of epitope recognition in MTBinfected individuals in different geographic regions (Valentini et al, 2017). These results are pertinent to novel vaccine development, as humoral immunity has gained increased interest in the battle against TB (Achkar et al, 2015;Niki et al, 2018).…”

Section: Discussionmentioning

confidence: 83%

Predicted Structural Variability of Mycobacterium tuberculosis PPE18 Protein With Immunological Implications Among Clinical Strains

Hakim

Yang

2021

Front. Microbiol.

View full text Add to dashboard Cite

Recent advancements in vaccinology have led to the development of the M72/AS01E subunit vaccine, of which the major component is the Mycobacterium tuberculosis (MTB) PPE18 protein. Previous studies have demonstrated the genetic variability of the gene encoding PPE18 protein and the resulting peptide changes in diverse clinical strains of MTB; however, none have modeled the structural changes resulting from these peptide changes and their immunological implications. In this study, we investigated the structural predictions of 29 variant PPE18 proteins previously reported. We found evidence that PPE18 is at least a two-domain protein, with a highly conserved first domain and a largely variable second domain that has different coevolutionary clusters. Further, we investigated putative epitope sites in the clinical variants of PPE18 using prediction software. We found a negative relationship between T-cell epitope number and residue variability, while B-cell epitope likelihood was positively correlated with residue variability. Moreover, we found far more residues in the second domain predicted to be B-cell epitopes compared with the first domain. These results suggest an important functional role of the first domain and a role in immune evasion for the second, which extends our knowledge base of the basic biology of the PPE18 protein and indicates the need for further study into non-traditional immunological responses to TB.

show abstract

“…The second study by Valentini et al used peptide arrays to dissect the epitope specific humoral immune responses across the entire M. tuberculosis protein molecules. 31 An interesting finding was that patients from South America recognized more peptides compared to patients from South Africa (both groups HIV-negative). 31 A study using peptide microarrays found that sera from patients with sarcoidosis and Löfgren's syndrome recognised 68 -78% M. tuberculosis peptides once again suggesting mycobacterial involvement in sarcoidosis.…”

Section: Immunological Studiesmentioning

confidence: 95%

“…31 An interesting finding was that patients from South America recognized more peptides compared to patients from South Africa (both groups HIV-negative). 31 A study using peptide microarrays found that sera from patients with sarcoidosis and Löfgren's syndrome recognised 68 -78% M. tuberculosis peptides once again suggesting mycobacterial involvement in sarcoidosis. 32 Using paleomicrobiology it is possible to study the evolution of MTBC over the past ten millennia and its association with human migration, providing new insight into the probable origin of the different MTBC bacterial lineages.…”

Section: Immunological Studiesmentioning

confidence: 95%

World TB Day 2017: Advances, Challenges and Opportunities in the “End-TB” Era

Petersen

Maeurer

Marais

et al. 2017

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era 4. Tackling TB Co-morbidities with infectious and noncommunicable diseases Co-infection with HIV greatly increases mortality and risk of treatment failure, 12 and diabetes mellitus also increases morbidity and mortality of TB. 13 These important co-morbidities clearly demonstrate that TB management needs an integrated approach and that every TB patient should be investigated for HIV and diabetes, and every patient with HIV and diabetes should be screened for active TB diseases and LTBI.Following a cohort of 1696 TB patients in Tanzania, Nagu and colleagues found that ART-näive TB/HIV patients had a seven-fold mortality risk (RR = 7.42; 95% CI: 3.87, 14.22; p < 0.0001), whereas TB/HIV patients on ART had a five-fold mortality risk (RR = 4.78; 95% CI: 2.41, 9.49; p < 0.0001). 12 The median time to death was shortest among ART-näive TB/HIV patients (thirty-six days). A thirty-day increase on ART duration associated with a 3% mortality reduction (RR = 0.97; 95% CI: 0.95, 0.99; p < 0.02), independent of CD4+ T lymphocyte count and ART regimen. 12 Diabetes mellitus, DM, increases the risk of developing TB by two to three fold and increases the risk of TB treatment failure, relapse and death. 13 Hypertension is an increasing problem

show abstract

Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays

Cited by 6 publications

References 46 publications

Peptide-Based Vaccines for Tuberculosis

Peptide-Based Vaccines for Tuberculosis

Predicted Structural Variability of Mycobacterium tuberculosis PPE18 Protein With Immunological Implications Among Clinical Strains

World TB Day 2017: Advances, Challenges and Opportunities in the “End-TB” Era

Contact Info

Product

Resources

About